Related Experiment Videos
Bronchoplastic lobectomies for advanced carcinoma: functional changes and survival
Acta Chirurgica Belgica
|July 1, 1978
Summary
Sleeve bronchoplasty for lung cancer offers better functional outcomes than wedge resection, though both procedures have risks. Long-term survival varies, with some patients surviving over five years post-surgery.
Area of Science:
- Thoracic Surgery
- Surgical Oncology
- Pulmonary Medicine
Background:
- Bronchogenic carcinoma necessitates surgical intervention, with lobectomy being a common approach.
- Bronchoplastic techniques like sleeve and wedge resections aim to preserve lung function while removing tumors.
- Tumor staging (TNM) and lymph node involvement are critical prognostic factors in lung cancer.
Purpose of the Study:
- To evaluate the outcomes of sleeve versus wedge bronchoplasties in patients with bronchogenic carcinoma.
- To assess the impact of these surgical techniques on lung function and patient survival.
- To analyze complications and recurrence rates associated with sleeve and wedge lobectomies.
Main Methods:
- Retrospective analysis of 25 patients undergoing sleeve or wedge lobectomies for lung cancer.
- Tumor staging (T1-T3) and lymph node status (N0-N2) were documented.
- Post-operative pulmonary function tests (plethysmography, bronchospirography, Xe133 gammagraphy) were performed in a subset of patients.
Main Results:
- Sleeve resections showed preserved or improved lung dynamics, while wedge resections impaired all parameters.
- Two patients developed bronchopleural fistula, with one fatality; one patient experienced local recurrence.
- Twelve patients died of cancer with a mean survival of 16 months; four patients survived over 5 years.
Conclusions:
- Sleeve bronchoplasty may offer superior lung function preservation compared to wedge resection in lung cancer surgery.
- While complications like bronchopleural fistula can occur, long-term survival is achievable for select patients.
- Further research into optimizing bronchoplastic techniques is warranted to improve oncologic and functional outcomes.